The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion.
The decision to terminate the trial was based on a lack of study drug supply. The decision was not based on any safety concerns. The termination letter was sent on 11March2011.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
684
Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase Stratified by Prior Opioid Therapy
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Duration to Titrate Participants to Stable Dose
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Duration to Titrate Participants to Stable Dose Stratified by Prior Opioid Therapy
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Number of Titration Steps to Achieve Stable Dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Adamsville Family Medicine
Adamsville, Alabama, United States
Office of David McLain
Birmingham, Alabama, United States
Monte Sano Clinical Research, LLC
Huntsville, Alabama, United States
Tennessee Valley Pain Consultants Properties, LLC
Huntsville, Alabama, United States
Sunbelt Research Group, LLC
Mobile, Alabama, United States
Office of Vaughn H. Mancha, Jr., PC
Montgomery, Alabama, United States
Dedicated Clinical Research
Goodyear, Arizona, United States
Dedicated Clinical Research, Inc
Phoenix, Arizona, United States
Redpoint Research
Phoenix, Arizona, United States
Anasazi Internal Medicine, PC
Phoenix, Arizona, United States
...and 156 more locations
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Number of Titration Steps to Achieve Stable Dose Stratified by Prior Opioid Therapy
A dose was considered to be stable dose if it met all of the following criteria: dose was taken for at least 48 hours; investigator deemed the balance between an acceptable level of analgesia and/or function and tolerance of side effects had been achieved; and rescue medication use less than or equal to 2 doses per day.
Time frame: Baseline through Week 6
Percentage of Participants With Rescue Medications Usage During Titration
Rescue pain medications were used for supplemental analgesia for breakthrough pain during titration phase. Morphine sulfate IR tablet (less than 20 percent of the total daily dose of EMBEDA per IR dose), ibuprofen (up to 400 milligram (mg)/dose; not to exceed 1200 mg/day), and acetaminophen (up to 1000 mg/dose, not to exceed 4000 mg/day) were used as rescue medications.
Time frame: Baseline through Week 6
Change From Baseline in Brief Pain Inventory (BPI) at Visit 3 (First Visit After Successful Titration)
BPI is an 11-item self-report questionnaire: consist of 4 questions that assess pain intensity (worst, least, average, relief) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question answered on a scale range:0-10 (0%-100% for relief), '0=No pain/no relief/no interference and 10=Pain as bad as you can imagine/complete relief/ complete interference'.Measure can be scored by item, with lower scores being indicative of less pain or pain interference.
Time frame: Baseline, Visit 3 (up to Week 6)
Investigator's Level of Satisfaction With the EMBEDA Conversion Guide
The conversion assessment survey is a brief questionnaire using multiple choice options and numeric rating scale (NRS) with specified anchored responses ranging on a scale from 0-10 (0 = very dissatisfied, 5 = neutral, and 10=very satisfied) to assess the Investigator's level of satisfaction with the EMBEDA Conversion Guide.
Time frame: Week 6